Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
September 23, 2008
3 week radiation for breast cancer: What is the cosmetic end result?
Analysis of: Shorter Radiation for Cancer of the Breast | www.nytimes.com
Author: GLG Expert Contributor
Results are identicle (3 weeks v 5 in post lumpectomy radiation?)
September 22, 2008
Can physicians adapt to proposed IT requirements?
Analysis of: Stark Offers Bill to Hasten e-record Adoption | modernhealthcare.com
Author: GLG Expert Contributor
Adoption of mandatory computerization will be gently forced on physicians and their offices
September 19, 2008
I know, I know there is no money in diagnostics but....
Analysis of: Raising the Profile of Cancer of Unknown Primary | jco.ascopubs.org
Author: GLG Expert Contributor
RNA gene profiling will allow up to get a better handle on the primary site, especially with increasing targeting opportunities in many neoplasms.
September 18, 2008
"Star Wars" technology interfaces with radiation oncology
Analysis of: Proton Radiotherapy: A Review | www.nytimes.com
Author: GLG Expert Contributor
Proton beam therapy will effect the market place and force competition for oncology centers to get "the next best thing."
September 9, 2008
Velcade 1st line? No surprise.....
Analysis of: Velcade (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma | www.therapeuticsdaily.com
Author: GLG Expert Contributor
Velcade, given with Melphalan & Prednisone approved for use 1st line in non-transplant myeloma patients first line.
September 9, 2008
IT'S ALIVE!!?? Astra Zeneca's (AZ) Iressa (At least in Japan)
Analysis of: Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study | jco.ascopubs.org
Author: GLG Expert Contributor
2 separate studies show that: 1. "...there was no statistically significant difference in overall survival....for gefitinib compared with docetaxel. Gefitinib remains an effective treatment option for previously treated Japanese patients with NSCLC." http://jco.ascopubs.org/cgi/content/full/26/26/4244...
September 8, 2008
Think about the future and what this will lead to....
Analysis of: In Long-Awaited Maps of Cancer, The Breakthrough Is the Problem | online.wsj.com
Author: GLG Expert Contributor
Pharmacogenomics will lead to the development of targeting agents and offer true hope for the future.
September 2, 2008
GIST: So what else is new.....
Analysis of: Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery | www.therapeuticsdaily.com
Author: GLG Expert Contributor
Novartis is looking for approval for therapy in C-KIT + Gastrointestinal stromal tumors
August 29, 2008
Bcl-2 apoptosis inhibition: The next "best" thing?
Analysis of: Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents | jco.ascopubs.org
Author: GLG Expert Contributor
Bcl-2 inhibition by small molecules stands to be the next avenue for antineoplastic therapy- Looks like the real deal!
August 29, 2008
Amgen Rewords Label: Less Use of Procrit
Analysis of: Amgen Told to Reword Drug Label | www.nytimes.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
The FDA required Amgen to revise the label for Procrit and Aranesp so that these agents are not used until a patient's hemoglobin drops below 10 or in the setting of potentially curative therapy.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next41 to 50 of 1055

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617